Nucala is approved in Canada to treat hypereosinophilic syndrome.-GSK

The approval allows for Nucala to become the first and only targeted biologic treatment available for patients with this eosinophil-driven disease and represents the third approved indication for Nucala, which targets eosinophilic inflammation.

“HES is a rare and complex disease with a significant unmet need that may be filled with Nucala," said Marni Freeman, Country Medical Director at GSK Canada. “GSK is committed to improving the lives of those living with disease associated with uncontrolled eosinophilic inflammation, continuously innovating for this broad patient group. This approval brings new hope to Canadians living withhypereosinophilic syndrome and new options for the healthcare providers supporting them.”